United States: Life Sciences, Biotechnology & Nanotechnology

The US Departments of Health and Human Services, Labor, and the Treasury have issued a final rule updating the federal independent dispute resolution process under the No Surprises Act, addressing the substantial...

The Trump administration has decertified and defunded Hawaii’s Medicaid Fraud Control Unit (MFCU), withholding $3 million in federal funds. As detailed in a previous post, in May, the Office of Inspector General for the Department of Health and Human Services (HHS-OIG) informed every state of its intent to review the activities of its MFCU.

Private equity investment in healthcare and life sciences is evolving as investors prioritize high-quality, scalable assets with strong management teams in sectors resistant to technological disruption.

The FDA is taking a dual approach to artificial intelligence in the pharmaceutical sector, issuing compliance warnings for manufacturing while simultaneously encouraging AI innovation in clinical trials.

This monthly newsletter examines significant legal trends and landmark cases in tort law, including the Sixth Circuit's reversal of class certification, FDA's dual approach to AI regulation in pharmaceuticals, Minnesota's upcoming PFAS ban, and the Supreme Court's expansive interpretation of federal officer removal jurisdiction. These developments carry strategic implications for businesses navigating complex litigation and regulatory compliance across multiple industries.

Life sciences companies with promising science and strong management can still face severe financial distress due to failed trials, regulatory delays, or collapsed financing.

The U.S. pet industry has reached $158 billion in spending, driven by strong demand in food, treats, and veterinary care. As organizations face increasing operational disruptions from cyber threats...

On May 6, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of its “One-Day Inspectional Assessment” pilot program, an initiative designed to conduct shorter, more targeted inspections at certain FDA-regulated facilities across all FDA product areas, including food, drugs, biologics, and medical products.

On May 26, 2026, Eli Lilly announced that it had entered into agreements to acquire LimmaTech Biologics AG, Curevo Inc., and Vaccine Company, Inc. as part of its expanded research and development efforts in infectious disease.